The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis

EBioMedicine

Volumn 2, Issue 7, 2015, Pages 671-680

  Stark, Mitchell S ^a,b   Klein, Kerenaftali ^a   Weide, Benjamin ^c   Haydu, Lauren E ^d,e   Pflugfelder, Annette ^c,f   Tang, Yue Hang ^f   Palmer, Jane M ^a   Whiteman, David C ^a   Scolyer, Richard A ^d,e   Mann, Graham J ^d,e   Thompson, John F ^d,e   Long, Georgina V ^d,e   Barbour, Andrew P ^f   Soyer, H Peter ^f   Garbe, Claus ^c   Herington, Adrian ^b   Pollock, Pamela M ^b   Hayward, Nicholas K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Biomarker; Diagnostic; Melanoma; MicroRNA; MiRNA; Prognostic

Indexed keywords

LACTATE DEHYDROGENASE; MICRORNA; PROTEIN S100B;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICRORNA EXPRESSION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; SEROLOGY; TAQMAN ASSAY; TISSUE MICROARRAY; TUMOR GROWTH; VALIDATION PROCESS; BLOOD; COHORT ANALYSIS; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

ADULT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84951573363     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.05.011     Document Type: Article

References (42)

1. AIHW Australian Cancer Incidence and Mortality (ACIM) Books: Melanoma of the Skin 2014, AIHW, Canberra.
2. Allegra A., Alonci A., Campo S., et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int. J. Oncol. 2012, 41(6):1897-1912.
3. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27(36):6199-6206.
4. Bonazzi V.F., Stark M.S., Hayward N.K. MicroRNA regulation of melanoma progression. Melanoma Res. 2012, 22(2):101-113.
5. Boyle G.M., Woods S.L., Bonazzi V.F., et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res. 2011, 24(3):525-537.
6. Brochez L., Naeyaert J.M. Serological markers for melanoma. Br. J. Dermatol. 2000, 143(2):256-268.
7. Davidson M., Lorigan P., Larkin J. High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. Melanoma Manag. 2014, 1(1):7-10.
8. De Guire V., Robitaille R., Tetreault N., et al. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. Clin. Biochem. 2013, 46(10-11):846-860.
9. Deichmann M., Benner A., Bock M., et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J. Clin. Oncol. 1999, 17(6):1891-1896.
10. Finck S.J., Giuliano A.E., Morton D.L. LDH and melanoma. Cancer 1983, 51(5):840-843.
11. Flaherty K., Daud A., Weber J.S., et al. Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). ASCO Meeting Abstracts 2014, 32(9010).
12. Fleming N.H., Zhong J., da Silva I.P., et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer 2015, 121(1):51-59.
13. Friedman E.B., Shang S., de Miera E.V., et al. Serum microRNAs as biomarkers for recurrence in melanoma. J. Transl. Med. 2012, 10:155.
14. Grambsch P.M., Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81(3):515-526.
15. Greenberg E., Besser M.J., Ben-Ami E., et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals 2013, 18(6):502-508.
16. Guo H.B., Stoffel-Wagner B., Bierwirth T., Mezger J., Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur. J. Cancer 1995, 31A(6):924-928.
17. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363(8):711-723.
18. Hothorn T., Hornik K., Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J. Comput. Graph. Stat. 2006, 15(3):651-674.
19. Joseph R.W., Elassaiss-Schaap J., Wolchok J.D., et al. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstracts 2014, 32(3015).
20. Karakousis C.P., Balch C.M., Urist M.M., Ross M.M., Smith T.J., Bartolucci A.A. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann. Surg. Oncol. 1996, 3(5):446-452.
21. Kruijff S., Bastiaannet E., Kobold A.C., van Ginkel R.J., Suurmeijer A.J., Hoekstra H.J. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann. Surg. Oncol. 2009, 16(12):3455-3462.
22. Leidinger P., Keller A., Borries A., et al. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 2010, 10:262.
23. Leiter U., Eigentler T., Garbe C. Follow-up in patients with low-risk cutaneous melanoma: is it worth it?. Melanoma Manag. 2014, 1(2):115-125.
24. Margue C., Reinsbach S., Philippidou D., et al. Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?. Oncotarget 2015, [Epub ahead of print].
25. Mitchell P.S., Parkin R.K., Kroh E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(30):10513-10518.
26. Mueller D.W., Rehli M., Bosserhoff A.K. MiRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J. Invest. Dermatol. 2009, 129(7):1740-1751.
27. Noren Hooten N., Fitzpatrick M., Wood W.H., et al. Age-related changes in microRNA levels in serum. Aging 2013, 5(10):725-740.
28. Ono S., Oyama T., Lam S., Chong K., Foshag L.J., Hoon D.S. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 2015, 6(9):7053-7064.
29. Ristau J., Staffa J., Schrotz-King P., et al. Suitability of circulating miRNAs as potential prognostic markers in colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2014, 23(12):2632-2637.
30. Sakamoto Y., Ishiguro M., Kitagawa G. Akaike Information Criterion Statistics 1986, D. Reidel Publishing Company.
31. SEER SEER Cancer Statistics Review, 1975-2011 2014, National Cancer Institute, Bethesda, MD.
32. Sirott M.N., Bajorin D.F., Wong G.Y., et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993, 72(10):3091-3098.
33. Smit L.H., Korse C.M., Hart A.A., et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur. J. Cancer 2005, 41(3):386-392.
34. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366(8):707-714.
35. Stark M.S., Bonazzi V.F., Boyle G.M., et al. MiR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget 2015, (Advance Online Publications: Page 3).
36. Streicher K.L., Zhu W., Lehmann K.P., et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 2012, 31(12):1558-1570.
37. Tembe V., Schramm S.J., Stark M.S., et al. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. Pigment Cell Melanoma Res 2015, 28(3):254-266.
38. Vermont J., Bosson J.L., Francois P., Robert C., Rueff A., Demongeot J. Strategies for graphical threshold determination. Comput. Methods Prog. Biomed. 1991, 35(2):141-150.
39. Weide B., Elsasser M., Buttner P., et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br. J. Cancer 2012, 107(3):422-428.
40. Weide B., Richter S., Buttner P., et al. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS One 2013, 8(11):e81624.
41. Whipple C.A., Brinckerhoff C.E. BRAF (V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. Br. J. Cancer 2014, 111(8):1625-1633.
42. Wians F.H.J. Clinical laboratory tests: which, why, and what do the results mean?. Lab. Med. 2009, 40(2):105-113.